05:00 pm
Welcome and Introduction
Dr Dave MADGE
WUXI APPTEC, Cambridge, United Kingdom
Dave is responsible for the preclinical discovery platform with which WuXi AppTec supports its collaborators in Europe and Israel. With a background in medicinal chemistry, Dave joined WuXi AppTec 7 years ago, after working in biotech (VP Research, Xention), founding NCE Discovery (now Domainex), and supporting an integrated biomedical research group at University College London. Dave started his career at the Wellcome Foundation and received his Ph.D in Chemistry from Imperial College, London.
05:05 pm
L05 - Virtual Screening, the Rocket Booster of Drug Discovery
Dr Le CHANG
WUXI APPTEC, Wuhan, China
Dr. Le Chang joined WuXi AppTec in 2014. He is the director of International Discovery Service Unit (IDSU), Research Service Division (RSD). Dr. Chang received his Ph.D. in Organic Chemistry with Professor Zhen Yang in 2012 from Peking University. His graduate research focused on total synthesis of complex natural products. After that, Dr. Chang continued his research in Professor Xiang Wang’s group as a research fellow at University of Colorado Boulder (2012-2014), and work on diverse topics between transition metal-catalyzed chemical methodology and bio-inspired synthesis. His research interests mainly focus on synthetic organic chemistry and medicinal chemistry.
05:30 pm
L06 - Making Virtual Molecules Real - the Role of Automation
Dr Dave PARRY
INDEPENDENT CONSULTANT - DRUG DISCOVERY, Cambridge, United Kingdom
Dave has over 25 years in the pharma/biotech sector; 16 years in mid-sized biopharma initially as a medicinal chemist progressing through section leader, chemistry then director of technology at UCB. In 2009 he joined Cyclofluidic as executive director to lead the company and deliver the first fully integrated design, make and test platform for small molecule discovery and providing medicinal chemistry services to pharma, biotech and the not for profit sectors.
Dave now uses his experience and interest in small molecule discovery, technologies and biotech to advise a range of clients on both scientific and business issues. He has particular expertise in chemistry automation and integration, informatics, small business operational management and early stage drug discovery.
05:55 pm
Q&A Panel Discussion
Dr Le CHANG WUXI APPTEC, Wuhan, China
Dr Christian LEMMEN BIOSOLVEIT, St. Augustin, Germany
Dr Dave PARRY INDEPENDENT CONSULTANT - DRUG DISCOVERY, Cambridge, United Kingdom
Dr Janeta POPOVICI-MULLER RECTIFY PHARMACEUTICALS, Cambridge (MA), United States
Dr Thomas STEINBRECHER SCHRÖDINGER, Mannheim, Germany
06:30 pm
End of the Day